Uncertainty management in regulatory and health technology assessment decision-making on drugs: guidance of the HTAi-DIA Working Group

11Citations
Citations of this article
30Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Objectives: Uncertainty is a fundamental component of decision making regarding access to and pricing and reimbursement of drugs. The context-specific interpretation and mitigation of uncertainty remain major challenges for decision makers. Following the 2021 HTAi Global Policy Forum, a cross-sectoral, interdisciplinary HTAi-DIA Working Group (WG) was initiated to develop guidance to support stakeholder deliberation on the systematic identification and mitigation of uncertainties in the regulatory-HTA interface. Methods: Six online discussions among WG members (Dec 2021-Sep 2022) who examined the output of a scoping review, two literature-based case studies and a survey; application of the initial guidance to a real-world case study; and two international conference panel discussions. Results: The WG identified key concepts, clustered into twelve building blocks that were collectively perceived to define uncertainty: "unavailable,""inaccurate,""conflicting,""not understandable,""random variation,""information,""prediction,""impact,""risk,""relevance,""context,"and "judgment."These were converted into a checklist to explain and define whether any issue constitutes a decision-relevant uncertainty. Ataxonomy of domains inwhich uncertainty may exist within the regulatory-HTAinterface was developed to facilitate categorization. The realworld case study was used to demonstrate how the guidance may facilitate deliberation between stakeholders and where additional guidance development may be needed. Conclusions: The systematic approach taken for the identification of uncertainties in this guidance has the potential to facilitate understanding of uncertainty and its management across different stakeholders involved in drug development and evaluation. This can improve consistency and transparency throughout decision processes. To further support uncertainty management, linkage to suitable mitigation strategies is necessary.

Cite

CITATION STYLE

APA

Hogervorst, M. A., Vreman, R., Heikkinen, I., Bagchi, I., Gutierrez-Ibarluzea, I., Ryll, B., … Oortwijn, W. (2023). Uncertainty management in regulatory and health technology assessment decision-making on drugs: guidance of the HTAi-DIA Working Group. International Journal of Technology Assessment in Health Care, 39(1). https://doi.org/10.1017/S0266462323000375

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free